The FAMHP is launching HemoVigilance, a new online application for reporting serious adverse reactions related to the donation or transfusion of blood and blood components. The application also allows users to report any serious adverse incidents that have an impact on the quality and safety of labile blood components to the FAMHP.
The aim of haemovigilance is to ensure and continuously improve the quality and safety of blood, blood components and their administration.
For this reason, data on serious adverse reactions linked to blood donation or transfusion, as well as data on serious adverse incidents that may affect the quality and safety of labile blood components, are systematically recorded and assessed.
Since March 2026, all notifications must be submitted via the new online application HemoVigilance, which replaces the previous online system.
Contact persons in blood transfusion establishments and hospitals can report serious adverse reactions and incidents to the FAMHP quickly and easily via HemoVigilance.
The application supports the broader mission of the FAMHP: to ensure the quality, safety and efficacy of human bodily material (including blood), from collection to use, and to safeguard its availability.
More information
Notification procedures
The HemoVigilance application
User guide for the HemoVigilance web application (version FR/version NL)